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Abstract
A 79-year-old female with a 2-month history of newly diagnosed myelodysplastic syndrome for which she received
blood transfusion with darbepoetin alfa presented with bilateral anterior uveitis 1 day after her fourth transfusion.
On exam, visual acuity was 20/20 in both eyes with biomicroscopy notable for conjunctival injection and anterior
chamber cell and flare consistent with anterior uveitis. She had no systemic symptoms, no history of eye trauma,
and no known infections. This case, along with prior reports in the literature, suggests that anterior uveitis may be
an idiosyncratic complication of darbepoetin alfa therapy.
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Findings
Introduction
The proportion of uveitis cases attributed to drug-induced
uveitis is reportedly less than 0.5 % [1]. Drug-induced uve-
itis more typically is caused by intraocular or topical rather
than systemic medications [2]. However, systemic medica-
tions have become increasingly recognized as potential
causes of uveitis. Several drugs are now more definitively
associated with anterior uveitis, such as cidofovir, rifabutin,
sulfonamides, bisphosphonates, fluoroquinolones, and di-
ethylcarbamazine [3, 4]. Recognizing potential causes of
medication-related intraocular inflammation is important
because it can avoid unnecessary workups and may allow
for clinical improvement by stopping the causative agent.
Although not well established, an association between
epoetin alfa, a human recombinant erythropoietin, and
anterior uveitis has been reported previously in the lit-
erature, with 13 patients across three medical centers
developing anterior uveitis after receiving epoetin alfa
during hemodialysis [2]. All of these patients were
undergoing hemodialysis for end stage renal failure and
receiving epoetin alfa for chronic anemia [2].
Case report
A 79-year-old Caucasian female presented with acute
onset, 1-day history of bilateral blurry vision, eye
redness, photophobia, and tearing. Past medical history
included a new diagnosis of myelodysplastic syndrome
2 months prior, for which she had received four blood
transfusions with darbepoetin alfa, a longer-acting
human recombinant erythropoietin. Her last transfusion
with darbepoetin alfa was 1 day before presentation. She
reported no other systemic symptoms, eye trauma, or
underlying infections. She had no history of ocular
inflammation or infection prior to beginning blood
transfusions with darbepoetin alfa, which includes a
1-month period in which she had myelodysplastic
syndrome but had not yet received any darbepoetin. She
noted bloodshot eyes and ocular tenderness to palpa-
tion after two of her prior blood transfusions with
darbepoetin alfa (to a degree that was less severe and
which had spontaneously resolved).
On exam, her visual acuity was 20/20-2 in each eye.
Her intraocular pressures were 15 mmHg in the right
eye and 16 mmHg in the left eye. Anterior segment
biomicroscopy revealed marked conjunctival injection,
grade 2+ cell and flare in the anterior chamber, and 2+
nuclear sclerosis in each eye. There was no vitreous
inflammation, and dilated fundus exam was normal
without inflammatory signs.
She was diagnosed with bilateral, acute anterior uveitis
and treated with prednisolone acetate 1 % hourly and
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homatropine 5 % three times a day. Two weeks later,
she reported that all her symptoms had rapidly resolved;
the visual acuity continued to be 20/20-2 in each eye
and biomicroscopy demonstrated complete resolution of
anterior uveitis.
Due to the temporal association of the patient’s darbe-
poetin alfa infusion with her acute onset anterior uveitis,
and history of previous suggestive similar episodes just
after infusions, a consensus decision was made with her
hematologist to discontinue the use of darbepoetin alfa
along with future blood product infusions. Treatment with
decitabine, a DNA hypomethylating agent that leads to
cellular differentiation, was initiated instead to help man-
age her myelodysplastic syndrome. The patient has since
received two infusions of blood products without further
episodes of ocular inflammation.
Discussion
Our patient represents the first described case of likely
darbepoetin alfa-induced anterior uveitis. It builds upon
the previous reports of epoetin-induced anterior uveitis
reported by Beiran et al. in 1996 [2].
The mechanism by which systemic medications induce
ocular inflammation is largely unknown, with the excep-
tion of bisphosphonates, which are associated with
increased intraocular inflammatory cytokines, elevated
C-reactive protein, interleukin-1, and interleukin-6 [5].
Beiran et al. postulated a mechanism whereby erythro-
poietin could induce an inflammatory effect by altering
prostaglandin E levels, breaking down the tight junctions
that form the blood-aqueous barrier [2]. Darbepoetin
alfa and epoetin alfa both have the same native protein
sequence, differing only in glycosylation patterns [6].
Therefore, it is likely that similar mechanisms contrib-
uted to the drug-induced anterior uveitis in these previ-
ously reported cases as well as our own.
Given our patient’s underlying myelodysplastic syndro-
me—which can be associated with the development of
autoimmune conditions—it also is possible that an auto-
immune process was the cause of her anterior uveitis
[7]. However, her reported history of two episodes of
photophobia and eye redness after previous infusions,
coupled with the absence of episodes both before beginning
and after discontinuation of darbepoetin alfa infusions,
suggests that this was indeed a drug-related anterior uveitis.
Further studies are needed to elucidate the mechanism and
strength between the association of darbepoetin alfa and
anterior uveitis.
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